Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
NCT07529808
Adenocarcinoma, Advanced Gastric Cancer
Fairfax, Virginia, United States
View Trial DetailsNCT Number: NCT07481110
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer.
It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.
Interested in participating?
Request Info19 year and older
All sexes
Observational
CHU Béni Messous, Algiers, Algeria
This is a non-interventional, observational, descriptive, cross-sectional clinical study with both prospective and retrospective data collection. It aims to describe the demographic, epidemiological, clinical, and outcome characteristics of approximately 1,000 patients with histologically confirmed gastric cancer in Algeria, and to analyze diagnostic and treatment practices.
Data will be collected from medical records and brief patient interviews (≈30 minutes). All information will be anonymized and used exclusively for research purposes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Non Inclusion Criteria:
Time frame: At Baseline ( Initial visit )
The patient's demographic profile will include age (years) and sex. Body Mass Index (BMI) will be calculated using weight (kg) and height (m) according to the formula BMI = weight / height² (kg/m²).
Time frame: At Baseline ( Initial visit )
The patient's sociological profile will be described as a composite variable : Education level (primary, secondary, university, other), Profession (employed, unemployed, retired, student, other), Place of residence (current residence; urban or rural), Origin (wilaya of birth/origin)
Time frame: At Baseline (Initial Visit)
Frequency (%) of epidemiological risk factors including family history of cancer, Helicobacter pylori infection, smoking status, alcohol consumption, dietary habits, and exposure to chemical substances.
Time frame: At Basline ( Initial Visit)
Distribution of patients according to initial symptoms, tumor localization, histological characteristics, biomarker expression, presence of metastases, and tumor stage according to the AJCC classification.
Time frame: At Baseline ( Initial Visit)
Distribution of treatment modalities including surgery (palliative or curative) and chemotherapy (adjuvant or treatment lines), as well as treatment response, complications, disease-free survival (DFS), and duration of response.
Time frame: At Basline (Initial Visit)
Proportion (%) of patients diagnosed using endoscopy, biopsy, or imaging, and median time to diagnosis (days) defined as the interval between first reported symptom and confirmed diagnosis.
Time frame: At Baseline (Initial Visit)
Proportion (%) of patients receiving surgery, chemotherapy, targeted therapy, immunotherapy, or palliative care, median time from confirmed diagnosis to initiation of first treatment (days), and proportion of patients with documented post-treatment follow-up.
Société Algérienne de Formation et Recherche en Oncologie
Other
Acronym: ECLIPSE-CG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07529808
Adenocarcinoma, Advanced Gastric Cancer
Fairfax, Virginia, United States
View Trial DetailsNCT06910657
Adenocarcinoma, Adnexal Diseases
St Louis, Missouri, United States
View Trial DetailsNCT07676461
Breast Cancer, Breast Diseases
Bogotá, Bogota D.C., Colombia
View Trial DetailsNCT07059884
Adnexal Diseases, Anal Cancer
Dublin, California, United States
View Trial Details